Developer docs
API playgroundTry for free, no card

Search company profiles

Phlow

Full company profile

uuid0000efq

Namestring
Phlow
Legal namestring
Phlow Corporation
Websiteurl
phlow-usa.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Phlow Corp. is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) for essential medicines. Founded in 2020 and headquartered in Richmond, Virginia, the company operates two newly operational cGMP manufacturing facilities capable of producing APIs at both kilogram and metric-ton scales using both batch and continuous processes. Its core technology platform is built around continuous flow chemistry and modern manufacturing methods intended to improve quality, reliability, and environmental outcomes relative to traditional batch manufacturing. The company is a Delaware public benefit corporation with B Corporation certification and operates a wholly-owned subsidiary, MedPhlow, focused on novel essential medicine delivery solutions.

The company's revenue model is dual-track. The dominant track is U.S. government contracting, with cumulative awarded contracts exceeding $600 million spanning federal agencies including BARDA, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), and FDA programs for medical countermeasures, essential medicines, and national preparedness initiatives. The secondary track is fee-for-service CDMO engagements with private pharmaceutical companies, including process development, analytical services, and commercial-scale API production. Phlow sells exclusively through direct enterprise engagement, not through traditional distribution channels. Notable commercial milestones include shipment of over 1.6 million vials of essential medicines to leading children's hospitals via the Children's Hospital Coalition, a flagship end-to-end domestic manufacturing collaboration with Fresenius Kabi for Epinephrine Injection, USP (announced February 2026), and selection for the first-ever FDA Commissioner's National Priority Voucher Pilot Program to domestically produce the ketamine API.

Phlow is augmenting its core manufacturing operations with an AI-driven chemistry platform developed in partnership with Enveda, which has generated nearly 20,000 unique reactions in three months and produced substantially more accurate yield-prediction models than those trained on public datasets. Additional program offerings include the cdmoX manufacturing services platform and SAPIR (Strategic Active Pharmaceutical Ingredient Reserve), a federal-aligned program designed to enhance domestic pharmaceutical supply chain resilience. Leadership was strengthened in 2025–2026 with the appointments of Tim M. Mayleben as Chairman of the Board (October 2025) and then Chief Executive Officer (May 2026), and Dawn Von Rohr as Chief Operating Officer (March 2026), both bringing extensive commercial pharmaceutical operating experience.

Short descriptiontext

Phlow Corp. is a U.S.-based pharmaceutical CDMO that develops and manufactures small molecule APIs for essential medicines using continuous flow chemistry, serving U.S. government agencies and pharmaceutical companies from operational cGMP facilities in Virginia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRichmond, United States
HQ citystring
Richmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, active pharmaceutical ingredient manufacturing, small molecule API development, continuous flow chemistry manufacturing, contract development manufacturing
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Government Contracts and CDMO Services
TypeManaged Services
Description

Phlow generates revenue through awarded government contracts exceeding $600 million for pharmaceutical manufacturing services, API production for essential medicines, and medical countermeasure development. Additionally provides fee-for-service CDMO offerings including process development, analytical services, and manufacturing for pharmaceutical companies.

globenewswire.com
2Private CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization services for private pharmaceutical companies, including advanced development and manufacturing solutions, process development, and commercial-scale API production.

phlow-usa.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Phlow is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) from early-stage process development through commercial-scale production. The company operates two cGMP facilities (kilo-scale and metric ton-scale) in Virginia, supports pharmaceutical companies and U.S. government agencies with API manufacturing, and runs dedicated programs including cdmoX, SAPIR, and Government/NGO services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Generated nearly 20,000 unique chemical reactions in 3 months, compressing development timelines from years to months
+2 more records
Product overview1 text field

Phlow is a modern, U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) offering an integrated suite of small molecule API development and manufacturing services. The core offering comprises Process Research & Development and Analytical Laboratories for early-stage development, a Kilo-Scale cGMP Facility for flexible small-batch production supporting preclinical and clinical stages, and a Metric Ton-Scale cGMP Facility for high-volume commercial manufacturing. These manufacturing capabilities are powered by advanced technologies including continuous flow chemistry. Supporting programs include the cdmoX program for customer engagements, the SAPIR (Strategic Active Pharmaceutical Ingredient Reserve) for government and national preparedness initiatives, and a Government/NGO services division for medical countermeasures. Recent additions include an AI-Driven Chemistry Platform developed in partnership with Enveda for accelerated process development, and domestic epinephrine API production as part of an end-to-end collaboration with Fresenius Kabi. The company operates from facilities in Richmond and Petersburg, Virginia, all within the Eastern U.S. timezone.

Product and service5 records
1Small Molecule API Development and Manufacturing
CategoryContract Development and Manufacturing (CDMO)
Description

End-to-end contract development and manufacturing of small molecule Active Pharmaceutical Ingredients (APIs), from early-stage process development and analytical support through kilo-scale and metric ton-scale cGMP commercial production, for pharmaceutical company customers.

2cdmoX Program
CategoryCDMO Service Program
Description

A dedicated CDMO program supporting customer drug programs through advanced development and manufacturing solutions, including continuous flow chemistry, aimed at reducing drug shortages and boosting U.S. pharmaceutical independence for pharmaceutical company customers.

3SAPIR (Strategic Active Pharmaceutical Ingredient Reserve)
CategoryGovernment / National Preparedness Service
Description

A strategic reserve program that enhances U.S. domestic pharmaceutical supply chain resilience and drug supply security by maintaining a reserve of strategically important active pharmaceutical ingredients for U.S. government and national preparedness customers.

4Government/NGO Pharmaceutical Services
CategoryGovernment / Defense Pharmaceutical Services
Description

Pharmaceutical development and manufacturing services for U.S. government agencies and NGOs, including medical countermeasures for chemical and biological threats, pediatric essential medicines, and national preparedness initiatives.

5Epinephrine Injection API Production
CategoryAPI Manufacturing
Description

Domestic manufacturing of the active pharmaceutical ingredient for Epinephrine Injection, USP, delivered as part of an end-to-end collaboration with Fresenius Kabi that handles formulation and finished dose production for U.S. hospitals and clinics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Collaboration supporting Virginia's biopharma ecosystem development. Phlow is part of the collaborative infrastructure including the Medicines for All Institute at Virginia Commonwealth University, Civica Rx, and the Alliance for Building Better Medicine, collectively creating a resilient regional biopharmaceutical ecosystem and reshoring essential medicine manufacturing.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-09
Description

First-ever end-to-end domestic manufacturing collaboration for Epinephrine Injection, USP. Phlow produces the active pharmaceutical ingredient (API) while Fresenius Kabi handles formulation and finished dose production for hospitals and clinics. Addresses chronic shortage risk for this essential medicine, with domestically manufactured product expected to be available to U.S. hospitals by 2027. Designed to be scalable to other essential medicines.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-14
Description

AI-driven chemistry partnership to accelerate domestic pharmaceutical development and transform drug substance manufacturing. Joint pilot program demonstrated that AI-driven chemistry can significantly compress development timelines from years to months. Generated nearly 20,000 unique reactions in three months, creating one of the largest high-quality chemical datasets in the field. AI models trained on internally generated data produced substantially more accurate yield predictions.

4U.S. Food and Drug Administration (FDA)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

Selected for the first-ever FDA Commissioner's National Priority Voucher Pilot Program to produce the active pharmaceutical ingredient for ketamine domestically. Initiative aims to strengthen U.S. pharmaceutical supply chain and address multi-year shortage of ketamine, leveraging vouchers to accelerate FDA review processes for domestic manufacturing projects.

globenewswire.com
5Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-22
Description

Partnership to develop medical countermeasure drug products that support the joint force and its allies in counteracting chemical and biological threats. Part of Phlow's government contract work supporting national preparedness.

phlow-usa.com
6Children's Hospital Coalition
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

First-of-its-kind initiative to combat pediatric drug shortages. Phlow has shipped over 1.6 million vials of essential medicines to leading children's hospitals across the country through this coalition.

phlow-usa.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Foundational government partnerships including federal contracts exceeding $600 million supporting domestic pharmaceutical manufacturing, essential medicine production, and national preparedness programs. Includes BARDA and other health security contracts.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cambrex is a leading small-molecule API CDMO offering process development, scale-up, and commercial manufacturing for pharmaceutical customers. Directly comparable to Phlow across small-molecule API development, cGMP manufacturing at multiple scales, and target customer base of pharma companies and government programs.

TypeDirect peer
Description

Curia Global is a contract development and manufacturing organization with deep small-molecule API capabilities across process R&D, analytical services, and commercial-scale manufacturing. Highly comparable to Phlow, including overlap via Phlow COO Dawn Von Rohr's prior SVP role leading global API operations at Curia.

TypeDirect peer
Description

Hovione is a privately-held CDMO specializing in small-molecule API development and manufacturing, including advanced particle engineering and continuous manufacturing. Comparable to Phlow in focus on small-molecule APIs, advanced manufacturing technologies, and integrated development-to-commercial services for pharmaceutical customers.

TypeBroad incumbent
Description

Patheon, now part of Thermo Fisher Scientific's pharma services division, is one of the largest global CDMOs offering small-molecule API and drug product manufacturing. Serves as a broad incumbent with overlapping capabilities to Phlow but a far larger scale, broader service portfolio, and global footprint.

TypeDirect peer
Description

Piramal Pharma Solutions is a global CDMO offering API development and manufacturing across multiple scales, including small molecules. Directly comparable to Phlow on small-molecule API CDMO services and customer overlap with pharmaceutical companies seeking contract manufacturing capacity.

TypeDirect peer
Description

AGC Pharma Chemicals (formerly AGC Asahi Glass) is a global CDMO providing small-molecule API development and manufacturing services, including highly potent APIs. Comparable to Phlow in small-molecule API focus, multi-scale cGMP manufacturing, and pharmaceutical customer base.

TypeDirect peer
Description

Veranova (formerly the Health division of Johnson Matthey) is a global CDMO specializing in small-molecule API development and manufacturing, including complex APIs. Directly comparable to Phlow on small-molecule API focus and integrated development-to-commercial manufacturing services.

TypeEmerging player
Description

Sai Life Sciences is an India-headquartered CDMO providing small-molecule API discovery, development, and manufacturing services. Comparable to Phlow on small-molecule API CDMO services, though Sai Life Sciences operates primarily from India-based facilities serving global pharmaceutical customers rather than a U.S.-domestic focus.

TypeEmerging player
Description

Antheia is a U.S.-based pharmaceutical ingredient manufacturer using synthetic biology and advanced manufacturing to transform essential medicine supply chains. Directly comparable to Phlow as a U.S.-focused domestic API manufacturing partner; Phlow has an active technology partnership with Antheia to bolster U.S. pharmaceutical supply chains.

TypeEmerging player
Description

Civica Rx is a non-profit generic drug company focused on addressing drug shortages and reducing reliance on overseas manufacturing through U.S.-based production. Part of Phlow's Virginia biopharma ecosystem collaboration alongside the Medicines for All Institute at VCU, addressing overlapping domestic essential-medicine supply challenges.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phlow

Pharmaceutical Contract Manufacturing (CDMO)phlow-usa.com

Phlow Corp. is a U.S.-based pharmaceutical CDMO that develops and manufactures small molecule APIs for essential medicines using continuous flow chemistry, serving U.S. government agencies and pharmaceutical companies from operational cGMP facilities in Virginia.

What Phlow does

Phlow Corp. is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) for essential medicines. Founded in 2020 and headquartered in Richmond, Virginia, the company operates two newly operational cGMP manufacturing facilities capable of producing APIs at both kilogram and metric-ton scales using both batch and continuous processes. Its core technology platform is built around continuous flow chemistry and modern manufacturing methods intended to improve quality, reliability, and environmental outcomes relative to traditional batch manufacturing. The company is a Delaware public benefit corporation with B Corporation certification and operates a wholly-owned subsidiary, MedPhlow, focused on novel essential medicine delivery solutions.

The company's revenue model is dual-track. The dominant track is U.S. government contracting, with cumulative awarded contracts exceeding $600 million spanning federal agencies including BARDA, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), and FDA programs for medical countermeasures, essential medicines, and national preparedness initiatives. The secondary track is fee-for-service CDMO engagements with private pharmaceutical companies, including process development, analytical services, and commercial-scale API production. Phlow sells exclusively through direct enterprise engagement, not through traditional distribution channels. Notable commercial milestones include shipment of over 1.6 million vials of essential medicines to leading children's hospitals via the Children's Hospital Coalition, a flagship end-to-end domestic manufacturing collaboration with Fresenius Kabi for Epinephrine Injection, USP (announced February 2026), and selection for the first-ever FDA Commissioner's National Priority Voucher Pilot Program to domestically produce the ketamine API.

Phlow is augmenting its core manufacturing operations with an AI-driven chemistry platform developed in partnership with Enveda, which has generated nearly 20,000 unique reactions in three months and produced substantially more accurate yield-prediction models than those trained on public datasets. Additional program offerings include the cdmoX manufacturing services platform and SAPIR (Strategic Active Pharmaceutical Ingredient Reserve), a federal-aligned program designed to enhance domestic pharmaceutical supply chain resilience. Leadership was strengthened in 2025–2026 with the appointments of Tim M. Mayleben as Chairman of the Board (October 2025) and then Chief Executive Officer (May 2026), and Dawn Von Rohr as Chief Operating Officer (March 2026), both bringing extensive commercial pharmaceutical operating experience.

Phlow firmographics

Firmographics
Name
Phlow
Legal name
Phlow Corporation
Website
https://phlow-usa.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Phlow Corp. is a U.S.-based pharmaceutical CDMO that develops and manufactures small molecule APIs for essential medicines using continuous flow chemistry, serving U.S. government agencies and pharmaceutical companies from operational cGMP facilities in Virginia.
Ownership category
akta.pro rank

Phlow industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical CDMO services
  • Active pharmaceutical ingredient manufacturing
  • Small molecule API development
  • Continuous flow chemistry manufacturing
  • Contract development manufacturing

Where Phlow is headquartered

Location

Headquarters

HQ city
Richmond
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Phlow business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Government Contracts and CDMO Services: Phlow generates revenue through awarded government contracts exceeding $600 million for pharmaceutical manufacturing services, API production for essential medicines, and medical countermeasure development. Additionally provides fee-for-service CDMO offerings including process development, analytical services, and manufacturing for pharmaceutical companies.
  2. Private CDMO Services: Contract development and manufacturing organization services for private pharmaceutical companies, including advanced development and manufacturing solutions, process development, and commercial-scale API production.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Phlow product offering

Product offering

Core offering

Phlow is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) from early-stage process development through commercial-scale production. The company operates two cGMP facilities (kilo-scale and metric ton-scale) in Virginia, supports pharmaceutical companies and U.S. government agencies with API manufacturing, and runs dedicated programs including cdmoX, SAPIR, and Government/NGO services.

Product overview

Phlow is a modern, U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) offering an integrated suite of small molecule API development and manufacturing services. The core offering comprises Process Research & Development and Analytical Laboratories for early-stage development, a Kilo-Scale cGMP Facility for flexible small-batch production supporting preclinical and clinical stages, and a Metric Ton-Scale cGMP Facility for high-volume commercial manufacturing. These manufacturing capabilities are powered by advanced technologies including continuous flow chemistry. Supporting programs include the cdmoX program for customer engagements, the SAPIR (Strategic Active Pharmaceutical Ingredient Reserve) for government and national preparedness initiatives, and a Government/NGO services division for medical countermeasures. Recent additions include an AI-Driven Chemistry Platform developed in partnership with Enveda for accelerated process development, and domestic epinephrine API production as part of an end-to-end collaboration with Fresenius Kabi. The company operates from facilities in Richmond and Petersburg, Virginia, all within the Eastern U.S. timezone.

Differentiator

Problem solved

Functional benefit

Products and services

  • Small Molecule API Development and Manufacturing End-to-end contract development and manufacturing of small molecule Active Pharmaceutical Ingredients (APIs), from early-stage process development and analytical support through kilo-scale and metric ton-scale cGMP commercial production, for pharmaceutical company customers.
  • cdmoX Program A dedicated CDMO program supporting customer drug programs through advanced development and manufacturing solutions, including continuous flow chemistry, aimed at reducing drug shortages and boosting U.S. pharmaceutical independence for pharmaceutical company customers.
  • SAPIR (Strategic Active Pharmaceutical Ingredient Reserve) A strategic reserve program that enhances U.S. domestic pharmaceutical supply chain resilience and drug supply security by maintaining a reserve of strategically important active pharmaceutical ingredients for U.S. government and national preparedness customers.
  • Government/NGO Pharmaceutical Services Pharmaceutical development and manufacturing services for U.S. government agencies and NGOs, including medical countermeasures for chemical and biological threats, pediatric essential medicines, and national preparedness initiatives.
  • Epinephrine Injection API Production Domestic manufacturing of the active pharmaceutical ingredient for Epinephrine Injection, USP, delivered as part of an end-to-end collaboration with Fresenius Kabi that handles formulation and finished dose production for U.S. hospitals and clinics.

Quantifiable outcome

  • Generated nearly 20,000 unique chemical reactions in 3 months, compressing development timelines from years to months
  • +2 more outcomes

Companies that use Phlow

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Phlow technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Phlow partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, flagship and core.

  • Virginia Innovation Partnership Corporation (VIPC)majorStrategic or Co-development Partner · 13 May 2026Collaboration supporting Virginia's biopharma ecosystem development. Phlow is part of the collaborative infrastructure including the Medicines for All Institute at Virginia Commonwealth University, Civica Rx, and the Alliance for Building Better Medicine, collectively creating a resilient regional biopharmaceutical ecosystem and reshoring essential medicine manufacturing.
  • Fresenius KabiflagshipStrategic or Co-development Partner · 9 February 2026First-ever end-to-end domestic manufacturing collaboration for Epinephrine Injection, USP. Phlow produces the active pharmaceutical ingredient (API) while Fresenius Kabi handles formulation and finished dose production for hospitals and clinics. Addresses chronic shortage risk for this essential medicine, with domestically manufactured product expected to be available to U.S. hospitals by 2027. Designed to be scalable to other essential medicines.
  • EnvedacoreTechnology or Integration · 14 January 2026AI-driven chemistry partnership to accelerate domestic pharmaceutical development and transform drug substance manufacturing. Joint pilot program demonstrated that AI-driven chemistry can significantly compress development timelines from years to months. Generated nearly 20,000 unique reactions in three months, creating one of the largest high-quality chemical datasets in the field. AI models trained on internally generated data produced substantially more accurate yield predictions.
  • U.S. Food and Drug Administration (FDA)majorStrategic or Co-development Partner · 16 October 2025Selected for the first-ever FDA Commissioner's National Priority Voucher Pilot Program to produce the active pharmaceutical ingredient for ketamine domestically. Initiative aims to strengthen U.S. pharmaceutical supply chain and address multi-year shortage of ketamine, leveraging vouchers to accelerate FDA review processes for domestic manufacturing projects.
  • Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND)majorStrategic or Co-development Partner · 22 July 2025Partnership to develop medical countermeasure drug products that support the joint force and its allies in counteracting chemical and biological threats. Part of Phlow's government contract work supporting national preparedness.
  • Children's Hospital CoalitioncoreStrategic or Co-development Partner · 1 January 2025First-of-its-kind initiative to combat pediatric drug shortages. Phlow has shipped over 1.6 million vials of essential medicines to leading children's hospitals across the country through this coalition.
  • U.S. Government (Federal Contracts)flagshipStrategic or Co-development Partner · 1 January 2021Foundational government partnerships including federal contracts exceeding $600 million supporting domestic pharmaceutical manufacturing, essential medicine production, and national preparedness programs. Includes BARDA and other health security contracts.

Scale indicators5 records

Recent moves7 records

Expansion highlights8 records

Phlow competitors and assessment

Company assessment

Direct peers

  • Cambrex: Cambrex is a leading small-molecule API CDMO offering process development, scale-up, and commercial manufacturing for pharmaceutical customers. Directly comparable to Phlow across small-molecule API development, cGMP manufacturing at multiple scales, and target customer base of pharma companies and government programs.
  • Curia Global: Curia Global is a contract development and manufacturing organization with deep small-molecule API capabilities across process R&D, analytical services, and commercial-scale manufacturing. Highly comparable to Phlow, including overlap via Phlow COO Dawn Von Rohr's prior SVP role leading global API operations at Curia.
  • Hovione: Hovione is a privately-held CDMO specializing in small-molecule API development and manufacturing, including advanced particle engineering and continuous manufacturing. Comparable to Phlow in focus on small-molecule APIs, advanced manufacturing technologies, and integrated development-to-commercial services for pharmaceutical customers.
  • Piramal Pharma Solutions: Piramal Pharma Solutions is a global CDMO offering API development and manufacturing across multiple scales, including small molecules. Directly comparable to Phlow on small-molecule API CDMO services and customer overlap with pharmaceutical companies seeking contract manufacturing capacity.
  • AGC Pharma Chemicals: AGC Pharma Chemicals (formerly AGC Asahi Glass) is a global CDMO providing small-molecule API development and manufacturing services, including highly potent APIs. Comparable to Phlow in small-molecule API focus, multi-scale cGMP manufacturing, and pharmaceutical customer base.
  • Veranova: Veranova (formerly the Health division of Johnson Matthey) is a global CDMO specializing in small-molecule API development and manufacturing, including complex APIs. Directly comparable to Phlow on small-molecule API focus and integrated development-to-commercial manufacturing services.

Broad incumbents

  • Patheon (Thermo Fisher Scientific): Patheon, now part of Thermo Fisher Scientific's pharma services division, is one of the largest global CDMOs offering small-molecule API and drug product manufacturing. Serves as a broad incumbent with overlapping capabilities to Phlow but a far larger scale, broader service portfolio, and global footprint.

Emerging players

  • Sai Life Sciences: Sai Life Sciences is an India-headquartered CDMO providing small-molecule API discovery, development, and manufacturing services. Comparable to Phlow on small-molecule API CDMO services, though Sai Life Sciences operates primarily from India-based facilities serving global pharmaceutical customers rather than a U.S.-domestic focus.
  • Antheia: Antheia is a U.S.-based pharmaceutical ingredient manufacturer using synthetic biology and advanced manufacturing to transform essential medicine supply chains. Directly comparable to Phlow as a U.S.-focused domestic API manufacturing partner; Phlow has an active technology partnership with Antheia to bolster U.S. pharmaceutical supply chains.
  • Civica Rx: Civica Rx is a non-profit generic drug company focused on addressing drug shortages and reducing reliance on overseas manufacturing through U.S.-based production. Part of Phlow's Virginia biopharma ecosystem collaboration alongside the Medicines for All Institute at VCU, addressing overlapping domestic essential-medicine supply challenges.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Phlow social profiles

Digital presence

Phlow compliance and trust

Trust signal

Compliance2 records

Phlow financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phlow leadership team

Management profile

Number of profiles

Profiles4 records

Phlow subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Phlow funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phlow M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phlow

What does Phlow do?

Phlow is a U.S.-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule active pharmaceutical ingredients (APIs) from early-stage process development through commercial-scale production. The company operates two cGMP facilities (kilo-scale and metric ton-scale) in Virginia, supports pharmaceutical companies and U.S. government agencies with API manufacturing, and runs dedicated programs including cdmoX, SAPIR, and Government/NGO services.

Is Phlow a public or private company?

Phlow is a private company. It is classified as venture growth investor backed and is currently operating.

When was Phlow founded?

Phlow was founded in 2020. It employs 101 to 250 people.

Where is Phlow based?

Phlow is headquartered in Richmond, United States, in the North America region.

How does Phlow make money?

Two revenue lines are on record. Government Contracts and CDMO Services are the primary driver. The others are private CDMO Services.

Who are Phlow's main competitors?

Direct peers on record are Cambrex, Curia Global, Hovione, Piramal Pharma Solutions, AGC Pharma Chemicals and Veranova. Patheon (Thermo Fisher Scientific) is listed as a broad incumbent. Emerging players are Sai Life Sciences, Antheia and Civica Rx.

Does Phlow have an API?

No public API is recorded for Phlow.

What industry is Phlow in?

Phlow's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Chemical & Engineering NewsUS offers funding to make medicines on shoreThe US federal government is providing funding to boost domestic production of active pharmaceutical ingredients (APIs) and finished medicines, specifically supporting the Advanced Pharmaceutical Manufacturing (APM) Tech Hub in Virginia with nearly $16 million. This initiative aims to reduce reliance on Chinese and Indian suppliers for essential generic drugs by establishing an integrated end-to-end manufacturing ecosystem involving companies like Civica Rx and Phlow. While experts view this as a positive step toward supply chain resilience, they argue that more extensive government support is required to make domestic production economically viable.BioSpacePhlow Applauds New U.S. Government Investment in Advancing America’s Domestic Medicine Supply ChainPhlow Corp. welcomed a $15.97 million EDA investment to launch the End-to-End Commercialization Project, led by Civica, Inc. The initiative will connect domestic API manufacturing, formulation, and commercialization for four sterile injectable medicines. Phlow, a founding member of the Alliance for Building Better Medicine, will contribute expertise alongside partners.GlobeNewswirePhlow Applauds New U.S. Government Investment in Advancing America's Domestic Medicine Supply ChainThe U.S. Economic Development Administration announced a $15.97 million investment through the Alliance for Building Better Medicine to launch the End-to-End Commercialization Project, which will establish an integrated domestic pharmaceutical commercialization pathway. The project, led by Civica, Inc. with Phlow Corp. as a founding member, will initially focus on four essential sterile injectable medicines used in emergency, anesthesia, and critical care settings. The initiative aims to strengthen America's pharmaceutical manufacturing ecosystem by connecting domestically sourced materials, API manufacturing, finished dose production, and regulatory approval within a coordinated national network of more than 55 public and private partners.citybizPhlow Appoints Sripathy Venkatraman as Chief Scientific OfficerPhlow Corp. has appointed Sripathy Venkatraman as Chief Scientific Officer to lead its scientific strategy and R&D activities as the company expands U.S.-based drug development and manufacturing capabilities. Venkatraman brings more than 25 years of pharmaceutical experience, including 23 years at contract manufacturer Curia where he held senior leadership positions overseeing R&D, process development, and manufacturing operations. The appointment supports Phlow's mission to strengthen domestic pharmaceutical manufacturing and improve the resilience of the U.S. medicine supply chain, including its work with the Strategic Active Pharmaceutical Ingredient Reserve.FinancialContent Business PagePhlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific OfficerPhlow Corp., a U.S.-based pharmaceutical contract development and manufacturing organization, announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of pharmaceutical experience, including 23 years at Curia, where he held senior executive roles overseeing research, development, and manufacturing. In his new role, he will lead Phlow's scientific strategy and development activities supporting the company's mission to strengthen America's domestic pharmaceutical supply chain.GlobeNewswirePhlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific OfficerPhlow Corp., a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO), announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer effective immediately. Venkatraman brings more than 25 years of pharmaceutical experience, having spent 23 years at Curia in senior executive roles including Interim President of Global R&D and Developmental Manufacturing. He will lead Phlow's scientific strategy and development activities, with a focus on advancing the company's integrated R&D capabilities and domestic manufacturing mission.BiobuzzVirginia’s Advanced Pharmaceutical Manufacturing Tech Hub Secures Federal Investment to Launch End-to-End Commercialization ProjectThe U.S. Economic Development Administration awarded a $15.97 million investment to Virginia's Advanced Pharmaceutical Manufacturing Tech Hub to launch the End-to-End Commercialization Project, led by Civica, Inc. and supported by Phlow Corp. and Occam Systems. The initiative aims to establish a fully domestic medicine supply chain for four essential sterile injectable medicines—ketamine, midazolam, norepinephrine, and succinylcholine—by connecting domestically sourced key starting materials, active pharmaceutical ingredients, finished dose formulations, FDA approval, and commercial manufacturing. The project builds on more than $1.7 billion in prior investment and aligns with broader efforts to strengthen America's pharmaceutical manufacturing resilience and reduce dependence on offshore production.AijournVirginia’s Advanced Pharmaceutical Manufacturing Tech Hub Secures Federal Investment to Launch End-to-End Commercialization ProjectVirginia's Advanced Pharmaceutical Manufacturing Tech Hub announced a $15.97 million investment from the U.S. Economic Development Administration to launch the End-to-End Commercialization Project, led by Civica, Inc. and supported by Phlow Corp. and Occam Systems along with 55 Alliance partners. The project will establish a fully domestic medicine supply chain for four essential sterile injectable medicines—ketamine, midazolam, norepinephrine, and succinylcholine—connecting key starting materials, API manufacturing, finished dose formulation, FDA approval, and commercial delivery. The initiative builds on over $1.7 billion in prior federal, state, and private investment and aims to strengthen America's pharmaceutical manufacturing capabilities while reducing dependence on global supply chains.PR NewswireVirginia's Advanced Pharmaceutical Manufacturing Tech Hub Secures Federal Investment to Launch End-to-End Commercialization ProjectThe Alliance for Building Better Medicine, Virginia's Advanced Pharmaceutical Manufacturing Tech Hub, received a $15.97 million investment from the U.S. Economic Development Administration to launch the End-to-End Commercialization Project. The initiative, led by Civica, Inc. and supported by Phlow Corp., Occam Systems, and 55 partners, will establish a fully domestic medicine supply chain for four essential sterile injectable medicines used in emergency, anesthesia, and critical care settings. The project builds on more than $1.7 billion in prior investment and represents broader efforts to reduce U.S. dependence on global pharmaceutical supply chains.